



CD34+ Events (/μl, N = 93)


Collective	Sample	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	54.3	43.4 - 65.2	54.3	14.8	93	80.6	76.3
	52	28.7	23.0 - 34.4	28.7	15.7	93	82.8	

Rate of success: 76,3%


CD45+ Events (/μl, N = 81)


Collective	Sample	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	16515	13212 - 19818	16515	7.01	81		
	52	12239	9791 - 14687	12239	6.68	81		

Rate of success: 92,6%


Viable CD45+ Events (/μl, N = 96)

Collective	Sample	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	12318	9854 - 14782	12318	12.9	96		
	52	9259	7407 - 11111	9259	12.7	96		



Rate of success: 84,4%



Viab le CD34+ Events (/μl, N = 96)

Collective	Sam- ple	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	44.3	35.4 - 53.2	44.3	15.2	96	81.3	69.8
	52	22.3	17.8 - 26.8	22.3	17.5	96	75.0	

Rate of success: 69,8%


Viab le CD34+ Events per viable CD45+ Events (% , N = 96)

Collective	Sam- ple	Target value	Review area	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	51	0.357	0.286 - 0.428	0.357	14.8	96		
	52	0.241	0.193 - 0.289	0.241	16.6	96		

Rate of success: 69,8%

